Categories: Health

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Fulcrum Therapeutics, Inc.

CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employee 70,000 options to purchase shares of the company’s common stock at an exercise price of $6.96 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, June 2, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

GlobeNews Wire

Recent Posts

NING Service Experience Centers Launch in Shanghai and Bangkok, Setting a New Benchmark for the NEV Aftermarket

NINGDE, China, Aug. 10, 2025 /PRNewswire/ -- On August 10th, NING Service, an independent aftermarket brand…

9 hours ago

Enovix Shareholder Second Reminder: Early Warrant Expiration Price Condition

Enovix Warrants: 14 of 14 Trading Days Above $10.50 August 08, 2025 18:57 ET  |…

19 hours ago

GVNR: Unlocking Permissionless, Peer-to-Peer Asset Control Across All Chains

Singapore, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Cross-chain infrastructure has long been burdened by bridge-related…

19 hours ago

Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order

August 08, 2025 18:28 ET  | Source: Aja Health and Wellness Inc. Not for dissemination…

20 hours ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…

20 hours ago